Ga-68-DOTA-TATE PET/CT for Discrimination of Tumors of the Optic Pathway

References

• Black P. Meningiomas. In: Cancer of the Nervous System. Black P, Loeffler JS, eds. Oxford, UK: Blackwell Science, 1997:349–362
   Google Scholar
• Batra M. [Radiological diagnostics of meningiomas]. Ophthalmologe 2013;110:415–420
   PubMedGoogle Scholar
• Wilhelm H. [Meningioma of the anterior visual pathways: Epidemiology and clinical symptoms]. Ophthalmologe 2013;110:403–407
   PubMedGoogle Scholar
• Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007;357:1821–1828
   PubMed Web of Science ®Google Scholar
• Sotoudeh H, Yazdi HR. A review on dural tail sign. World J Radiol 2010;28(2):188–192
   Google Scholar
• Afshar-Oromieh A, Giesel FL, Linhart HG, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imag 2012;39:1409–1415
   PubMed Web of Science ®Google Scholar
• Haug AR, Rominger A, Mustafa M, et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011;52:1679–1683
   PubMed Web of Science ®Google Scholar
• Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 1998;73:936–942
   PubMed Web of Science ®Google Scholar
• Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053–1056
   PubMed Web of Science ®Google Scholar
• Prasad V, Ambrosini V, Homman M, et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imag 2010;50:67–77
   Google Scholar
• Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68GA]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006;65:222–227
   PubMed Web of Science ®Google Scholar
• Gehler B, Paulsen F, Oksüz MO, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol 2009;4:56
   PubMedGoogle Scholar
• Yang SY, Park CK, Park SH, et al. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psych 2008;79:574–580
   PubMed Web of Science ®Google Scholar
• Cornelius JF, Langen KJ, Stoffels G, et al. Positron emission tomography imaging of meningioma in clinical practice: review of literature and future directions. Neurosurgery 2012;70:1033–1041
   PubMedGoogle Scholar
• Breeman WA, de Jong M, de Blois E, et al. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478–485
   PubMedGoogle Scholar
• Conry BG, Papathanasiou ND, Prakash V, et al. Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imag 2010;37:49–57
   PubMedGoogle Scholar
• Haas JF, Jaenisch W, Staneczek W. Newly diagnosed primary intracranial neoplasms in pregnant women: a population-based assessment. J Neurol Neurosurg Psychiatry 1986;49:874–880
   PubMed Web of Science ®Google Scholar
• Shitara S, Nitta N, Fukami T, et al. Tuberculum sellae meningioma causing progressive visual impairment during pregnancy. Neurol Med Chir 2012;52:607–611
   PubMed Web of Science ®Google Scholar
• Kanaan I, Jallu A, Kanaan H. Management strategy for meningioma in pregnancy: a clinical study. Skull Base 2003;13:197–203
   PubMed Web of Science ®Google Scholar
• Roser F, Nakamura M, Ritz R, et al. Proliferation and progeseron receptor status in benign meningiomas are not age dependent. Cancer 2005;104:598–601
   PubMedGoogle Scholar
• Wahab M, Al-Azzawi R. Meinigioma and hormonal influences. Climacteric 2003;6:285–292
   PubMed Web of Science ®Google Scholar
• Bonavolontà G. Postoperative blindness following orbital surgery. Orbit 2005;24:195–200
   PubMedGoogle Scholar
• Oya S, Kim SH, Sade B, et al. The natural history of intracranial meningiomas. J Neurosurg 2011;114:1250–1256
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Kooij PP, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]Octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47:1599–1606
   PubMed Web of Science ®Google Scholar
• Bartolomei M, Bodei L, De Cicco C, et al. Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imag 2009;36:1407–1416
   PubMed Web of Science ®Google Scholar
• Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 2012; 53:1686–1692
   PubMed Web of Science ®Google Scholar
• Brix G, Belleman ME, Hauser H, et al. Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination. Nuklearmedizin 2002;41:184–190
   PubMedGoogle Scholar
• Scheidhauer K, Hildebrandt G, Luyken C, et al. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab Res Supp 1993;27:59–62
   PubMedGoogle Scholar
• Chen CC, Czerwiec FS, Feuillan PP. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med 1998;39:238–240
   PubMedGoogle Scholar
• Elgeti F, Amthauer H, Denecke T, et al. Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours. Nuklearmedizin 2008;47:261–265
   PubMedGoogle Scholar
• Armani C, Catalani E, Balbarini A, et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol 2007;81:845–855
   PubMedGoogle Scholar